An Open-Label, Phase I Study of GDC-0927 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Dec 2017
At a glance
- Drugs RG 6047 (Primary)
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions
- Sponsors Genentech
- 12 Dec 2017 Planned primary completion date changed from 30 Nov 2017 to 21 Dec 2018.
- 05 May 2015 Planned End Date changed from 1 Nov 2018 to 1 Dec 2018 as reported by ClinicalTrials.gov.
- 16 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.